135015-84-8

Upstream product

• 109072-25-5 2-ethyl-4(1H)-quinolone 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 143805-52-1 2-ethyl-4-[(2'-(1-(4-nitrophenyl)-1H-tetrazol-5-yl)biphenyl-4-yl)methoxy]quinoline 
• 108-10-1 4-methyl-2-pentanone 
• 143805-61-2 2-ethyl-4-[(2'-(1-(pyridin-4-yl)-1H-tetrazol-5-yl)biphenyl-4-yl)methoxy]quinoline 
• 107-03-9 1-thiopropane 
• 62-53-3 aniline 
• 109245-01-4 ethyl 3-(phenylamino) pent-2-enoate 
• 30414-53-0 methyl propanoyl acetate 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES AND USE THEREOF AS ANGIOTENSIN II ANTAGONISTS

The invention concerns pharmaceutically useful novel compounds of the formula I, in which R 1, R 2, R 3, R 4, R 5, Ra, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment. STR1

Chemical process for making angiotesin II antagonist compounds

The invention provides a novel chemical process for the manufacture of quinoline, pyridine and imidazole derivatives of the formula IV wherein Q, Y 1 and Y 2 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula VI as defined herein.

Heterocyclic boron compounds as intermediates for angiotensin II antagonists

The invention concerns novel boron compounds of the formula IV, in which Q, Y 1, G 1 and G 2 have the various meanings defined herein, and their acid and base addition salts. The said compounds are useful in the manufacture of certain quinoline, pyridine and imidazole derivatives which have angiotensin II inhibitory activity. The invention also provides novel processes for the production of the quinoline, pyridine and imidazole derivatives. STR1

New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4- (biphenylylmethoxy)quinoline derivatives

A novel series of nonpeptidic angiotensin II (AII) receptor antagonists is reported, derived from linkage of the biphenylcarboxylic acid or biphenylyltetrazole moiety found in previously described antagonists via a methyleneoxy chain to the 4-position of